Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia

PURPOSE: The anti-CD19 chimeric antigen receptor T-cell therapy tisagenlecleucel (CTL019) has an 81% response rate in children with relapsed or chemotherapy refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). Cytokine release syndrome (CRS) is a life-threatening treatment-related toxicity th...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Frey, Noelle V., Shaw, Pamela A., Hexner, Elizabeth O., Pequignot, Edward, Gill, Saar, Luger, Selina M., Mangan, James K., Loren, Alison W., Perl, Alexander E., Maude, Shannon L., Grupp, Stephan A., Shah, Nirav N., Gilmore, Joan, Lacey, Simon F., Melenhorst, Jos J., Levine, Bruce L., June, Carl H., Porter, David L.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2020
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8312030/
https://ncbi.nlm.nih.gov/pubmed/31815579
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.01892
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller